Free Trial

Positive Musings On COVID-19 Vaccine

MARKET TALK

BBG covers headlines surrounding Pfizer's COVID-19 vaccine.

  • The company notes that its BNT162 MRNA-based vaccine has moved into phase 2 of 3 in its trial.
  • It is on track to receive regulatory review as soon as October.
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.